한글목차

영양 유전체학은 특정 유전자 변이 또는 다형성의 존재를 연구하는 것으로, 대부분의 경우 특정 질병 과정에 대한 소인을 의미하며, 개인별 맞춤 영양 섭취와 같은 환경 및 행동 요인의 복잡한 상호작용을 통해 예방할 수 있습니다. 예방할 수 있습니다.

영양유전체학은 특정 영양소나 건강보조식품이 개인의 유전적 체질 발현에 미치는 영향을 연구하는 학문입니다.

비만, 당뇨병, 심혈관 질환과 같은 만성질환의 유병률 증가는 영양유전체학 검사 시장의 성장을 가속하고 있습니다. 지난 10년간 프로테오믹스, 유전체학, 대사체학 등 오믹 기술이 급속히 발전하고 첨단 바이오인포매틱스와 결합하여 단백질 경로에 기반한 질병을 규명하는 데 널리 활용되고 있습니다. 현재 영양유전체학 지식은 당뇨병, 암, 비만과 같은 식습관 관련 질환의 치료에 어느 정도 활용되고 있으며, 이는 영양유전체학 검사 시장 규모를 크게 증가시키고 있습니다.

영양 유전체학 검사 결과의 정확성과 신뢰성은 많은 소비자들의 주요 관심사 중 하나입니다. 영양유전체학 검사를 포함한 소비자 직접 검사에는 그 주장을 지원할 수 있는 다양한 수준의 증거가 있습니다. 일부 소비자 직접 검사에는 검사에서 제공하는 정보를 지원하는 과학적, 임상적 데이터가 많은 반면, 일부 소비자 직접 검사에는 지원하는 데이터가 많지 않은 경우도 있습니다. 또한 다양한 유전자 변이가 질병에 기여하는 역할에 대한 임상계의 의견 차이도 검사의 정확성과 신뢰성에 영향을 미치는 요인입니다. 또한 모든 변이가 개인의 질병이나 상태의 위험에 기여하는 것은 아니기 때문에 음성 결과가 나왔다고 해서 그 사람이 특정 질병이나 상태의 위험에서 벗어나는 것은 아니라는 점을 고객이 이해하는 것이 중요합니다. 회사마다 다른 변종을 검사하기 때문에 동일한 뉴트리노믹스 검사에서 동일한 질병에 대해 서로 다른 결과를 얻을 수 있습니다. 따라서 영양유전체학 검사의 주문과 결과 해석은 고객 스스로의 판단에 따라 결정해야 합니다. 따라서 영양유전체학 검사 결과는 정확하고 신뢰할 수 있는 것으로 간주되지 않아 전체 수요를 더욱 저해하고 있습니다.

스포츠 영양유전체학은 영양유전체학 검사 시장에 또 다른 중요한 기회입니다. 따라서 운동선수들은 건강 상태를 개선하기 위해 맞춤형 식단을 요구하고 있습니다. 운동선수 집단의 맞춤 영양학은 개인의 유전자 프로파일에 맞추어 식단 권장 사항을 조정하여 건강, 체성분 및 운동 성능을 최적화하는 것을 목표로 합니다. 스포츠 영양사 및 관리 영양사들은 다양한 스포츠 인구에 대응하기 위해 일반적인 식단 지침에 추가적인 분석을 추가하는 데 오랜 시간 동안 숙련되어 왔습니다. 그러나 여전히 일반적인 '획일적인' 권장 사항은 여전히 남아 있습니다. 유전자의 차이는 영양소 및 식품 생리활성물질의 흡수, 대사, 섭취, 이용 및 배설에 영향을 미치는 것으로 알려져 있으며, 궁극적으로 많은 대사 경로에 영향을 미칩니다. 영양유전체학(Nutrigenomics)과 영양유전체학(Nutrigenetics)은 유전체 정보와 유전자 검사 기술을 이용한 실험적 접근법으로, 영양소 및 기타 식품 성분에 대한 선수의 반응을 변화시키는 데 있으며, 개인의 유전적 차이가 어떤 역할을 하는지를 연구하는 학문입니다. 인체공학 보조제에 대한 반응에 대한 유전적 변이가 운동 능력에 미치는 영향을 조사한 무작위 대조 시험은 거의 없지만, 운동 및 스포츠 수행 능력에 영향을 미치는 영양 상태의 바이오마커에 대한 유전자와 식단의 상호 작용과 관련된 연구 기반은 점점 더 커지고 있습니다. 이 기반은 스포츠 영양 유전체학 분야가 계속 발전할 수 있는 토대를 형성하고 있습니다.

COVID-19 팬데믹은 영양유전체학 검사 시장의 성장에 큰 영향을 미쳤습니다. 이 팬데믹은 원격의료에 많은 신규 사용자를 도입하여 잠재적 경쟁자들에 대한 이점을 더욱 강화했습니다. 또한 COVID-19 팬데믹은 뉴트리노믹스 시장내 추가적인 업계 재편과 협업을 촉진했습니다. 또한 COVID-19 팬데믹와 그로 인한 소비자 행동과 기대치의 변화는 다양한 전통적 의료 서비스 프로바이더들이 대면 능력과 결합할 수 있는 원격의료 옵션을 평가하고 추구하게 만들었습니다. 또한 원격의료에 대한 인식, 수용, 이용은 COVID-19 팬데믹으로 인해 긍정적인 영향을 받았으며, 가상 진료에 대한 소비자의 수용성이 높아졌습니다. 이처럼 팬데믹은 원격의료 서비스 이용 증가로 이어졌으며, 이는 팬데믹 이후 기간 중 영양유전체학 시장을 촉진할 것으로 예상됩니다.

은행 사이버 보안 시장에서 사업을 운영하고 있는 기업으로는 Ancestry, Nutrigenomix, 23andMe Inc, DNAfit, GX Sciences Inc, Xcode Life, Koninklijke DSM N.V.(Royal DSM), BASF SE, Danone S.A., Danone S.A., The Gene Box 등이 있다, BASF SE, Danone S.A., The Gene Box 등이 있습니다.

이해관계자 주요 이점

• 이 보고서는 2022-2032년 영양유전체학 시장 분석 시장 부문, 현재 동향, 추정 동향 및 역학을 정량적으로 분석하여 일반적인 영양유전체학 시장 기회를 식별합니다.
• 시장 성장 촉진요인, 시장 성장 억제요인, 시장 기회와 관련된 정보와 함께 시장 조사를 제공합니다.
• Porter's Five Forces 분석은 이해 관계자가 이익 중심의 비즈니스 결정을 내리고 공급자와 구매자의 네트워크를 강화할 수 있도록 구매자와 공급자의 잠재력을 밝힙니다.
• 영양유전체학 시장 세분화에 대한 상세한 분석은 시장 기회를 결정하는 데 도움이 될 것입니다.
• 각 지역의 주요 국가는 세계 시장에 대한 매출 기여도에 따라 매핑되어 있습니다.
• 시장 기업의 포지셔닝은 벤치마킹을 용이하게 하고 시장 기업의 현재 위치에 대한 명확한 이해를 제공합니다.
• 지역별 및 세계 영양유전체학 시장 동향, 주요 기업, 시장 부문, 용도, 시장 성장 전략 등에 대한 분석이 포함됩니다.

이 보고서에서 가능한 커스터마이징

• 소비자 구매행동 분석
• 최종사용자 선호도 및 페인 포인트
• 투자 기회
• 지역별 신규 진출기업
• 기술 동향 분석
• 시장 진출 전략
• 제품/부문별 시장 세분화
• 통증 포인트 분석
• 규제 가이드라인
• 전략적 제안
• 고객의 관심사에 특화된 추가 기업 개요
• 국가별 또는 지역별 추가 분석 - 시장 규모 및 전망
• 크리스크로스 부문 분석 - 시장 규모 및 예측
• 기업 개요 확장 리스트
• 과거 시장 데이터
• 세계/지역/국가별 기업의 시장 점유율 분석
• SWOT 분석

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장의 정의와 범위
• 주요 조사 결과
  • 영향요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 촉진요인
  • 억제요인
  • 기회
• 시장 점유율 분석
• 브랜드 점유율 분석
• 밸류체인 분석
• 규제 가이드라인
• 주요 규제 분석

제4장 영양유전체학 시장 : 제품 유형별

• 개요
• 시약과 키트
• 서비스

제5장 영양유전체학 시장, 용도별

• 개요
• 비만
• 당뇨병
• 심혈관질환
• 암연구

제6장 영양유전체학 시장 : 최종사용자별

• 개요
• 온라인 플랫폼
• 병원과 진료소
• 기타

제7장 영양유전체학 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 스페인
  • 이탈리아
  • 기타
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 한국
  • 호주
  • 기타
• 라틴아메리카·중동 및 아프리카
  • 브라질
  • UAE
  • 사우디아라비아
  • 남아프리카공화국
  • 기타

제8장 경쟁 상황

• 서론
• 주요 성공 전략
• 주요 10사의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝, 2022년

제9장 기업 개요

• Cura Integrative Medicine
• Holistic Health
• Metagenics, Inc.
• GX Sciences Inc.
• The Gene Box
• Nutrigenomix Inc.
• Xcode Life
• DNA Life
• Interleukin Genetics
• Genova Diagnostics

영문목차

Nutrigenetics studies the presence of a particular gene variant or polymorphism that in most cases merely connotes a predisposition to a particular disease process that may be prevented through a complex interplay of environmental and behavioral factors such as a personalized nutrition. Nutrigenomics refers to the study of the effects of specific nutrients or nutraceuticals on the expression of an individual's genetic makeup.

Rising prevalence of chronic diseases such as obesity, diabetes, and cardiovascular diseases is driving the growth of the nutrigenomics testing market. Over the past decade, rapid advancements in omic technologies such as proteomics, genomics, and metabolomics are combining with advanced bioinformatics to be broadly used for identifying diseases based on protein pathways. Currently, the findings of nutrigenomics have been used to some extent to treat diseases with a diet component like diabetes, cancer, and obesity, significantly boosting the nutrigenomics testing market size.

Accuracy and reliability of the nutrigenomic test findings is one of the major concerns for most of the consumers. Direct-to-consumer tests including nutrigenomic tests have varying levels of evidence that support their claims. Some direct-to-consumer tests have more scientific and clinical data to support the information provided in the test, while other tests do not have as much supporting data. Furthermore, disagreements in the clinical community about the role that different genetic variants are contributing to the disease is another reason affecting the accuracy and reliability of the test. Moreover, not all variants contribute to an individual's risk of getting a disease or condition, so it is important that customers understand that a negative result does not mean that the individual is free from the risk of developing a particular disease or condition. As different companies test for the different set of variants, therefore the same nutrigenomics tests might provide different results for the same disease. Thus, customers need to use their own judgment while ordering and interpreting the results from nutrigenomic tests. Therefore, nutrigenomics test results are not considered as accurate and reliable, further hampering the overall demand.

Sport nutrigenomics is another significant opportunity for nutrigenomics testing market. Thus, athletes are looking for tailor-made diets for improving their health status. Personalized nutrition in athletic populations aims in optimizing health, body composition, and exercise performance by targeting dietary recommendations to an individual's genetic profile. Sport dietitians and nutritionists have long been skilled at placing additional analysis on the one-size-fits-all general population dietary guidelines to accommodate various sporting populations. However, generic 'one-size-fits-all' recommendations still remain. Genetic differences are known to impact absorption, metabolism, uptake, utilization, and excretion of nutrients and food bio actives, which ultimately affects a number of metabolic pathways. Nutrigenomics and nutrigenetics are experimental approaches that use genomic information and genetic testing technologies to examine the role of individual genetic differences in modifying an athlete's response to nutrients and other food components. Although there have been few randomized, controlled trials examining the effects of genetic variation on performance in response to an ergogenic aid, there is a growing foundation of research linking gene-diet interactions on biomarkers of nutritional status, which impact exercise and sport performance. This foundation forms the basis from which the field of sport nutrigenomics continues to develop.

The COVID-19 pandemic had significant impacts on the nutrigenomics testing market growth. The pandemic introduced many new users to telehealth and further reinforced its benefits to potential competitors. In turn, the COVID-19 pandemic has also driven additional industry consolidation or collaboration within the nutrigenomics market. Furthermore, the COVID-19 pandemic, and its resulting changes in consumer behavior and expectations, has also caused various traditional healthcare providers to evaluate and pursue telehealth options that can be paired with their in-person capabilities. Also, telehealth awareness, acceptance, and usage have been positively impacted by the COVID-19 pandemic, leading to increased consumer acceptance of virtual care. Thus, the pandemic led to an increase in the utilization of telehealth services, which is anticipated to boost the nutrigenomics market in the post-pandemic period.

Some of the companies operating in the cybersecurity in banking market are Ancestry, Nutrigenomix, 23andMe Inc., DNAfit, GX Sciences Inc., Xcode Life, Koninklijke DSM N.V. (Royal DSM), BASF SE, Danone S.A., and The Gene Box.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the nutrigenomics market analysis from 2022 to 2032 to identify the prevailing nutrigenomics market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the nutrigenomics market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global nutrigenomics market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Consumer Buying Behavior Analysis
• End user preferences and pain points
• Investment Opportunities
• Upcoming/New Entrant by Regions
• Technology Trend Analysis
• Go To Market Strategy
• Market share analysis of players by products/segments
• Pain Point Analysis
• Regulatory Guidelines
• Strategic Recommedations
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Criss-cross segment analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Market share analysis of players at global/region/country level
• SWOT Analysis

Key Market Segments

By Product Type

• Reagents and Kits
• Services

By Applications

• Diabetes
• Cardiovascular Diseases
• Cancer Research
• Obesity

By End User

• Online Platforms
• Hospitals and Clinics
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Cura Integrative Medicine
• Holistic Health
• Metagenics, Inc.
• GX Sciences Inc.
• The Gene Box
• Nutrigenomix Inc.
• Xcode Life
• DNA Life
• Interleukin Genetics
• Genova Diagnostics

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
• 3.4. Market dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities
• 3.5. Market Share Analysis
• 3.6. Brand Share Analysis
• 3.7. Value Chain Analysis
• 3.8. Regulatory Guidelines
• 3.9. Key Regulation Analysis

CHAPTER 4: NUTRIGENOMICS MARKET, BY PRODUCT TYPE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Reagents and Kits
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Services
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country

CHAPTER 5: NUTRIGENOMICS MARKET, BY APPLICATIONS

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Obesity
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Diabetes
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Cardiovascular Diseases
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country
• 5.5. Cancer Research
  • 5.5.1. Key market trends, growth factors and opportunities
  • 5.5.2. Market size and forecast, by region
  • 5.5.3. Market share analysis by country

CHAPTER 6: NUTRIGENOMICS MARKET, BY END USER

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Online Platforms
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Hospitals and Clinics
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Others
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country

CHAPTER 7: NUTRIGENOMICS MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by Product Type
  • 7.2.3. Market size and forecast, by Applications
  • 7.2.4. Market size and forecast, by End User
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Market size and forecast, by Product Type
    • 7.2.5.1.2. Market size and forecast, by Applications
    • 7.2.5.1.3. Market size and forecast, by End User
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Market size and forecast, by Product Type
    • 7.2.5.2.2. Market size and forecast, by Applications
    • 7.2.5.2.3. Market size and forecast, by End User
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Market size and forecast, by Product Type
    • 7.2.5.3.2. Market size and forecast, by Applications
    • 7.2.5.3.3. Market size and forecast, by End User
• 7.3. Europe
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by Product Type
  • 7.3.3. Market size and forecast, by Applications
  • 7.3.4. Market size and forecast, by End User
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Market size and forecast, by Product Type
    • 7.3.5.1.2. Market size and forecast, by Applications
    • 7.3.5.1.3. Market size and forecast, by End User
    • 7.3.5.2. UK
    • 7.3.5.2.1. Market size and forecast, by Product Type
    • 7.3.5.2.2. Market size and forecast, by Applications
    • 7.3.5.2.3. Market size and forecast, by End User
    • 7.3.5.3. France
    • 7.3.5.3.1. Market size and forecast, by Product Type
    • 7.3.5.3.2. Market size and forecast, by Applications
    • 7.3.5.3.3. Market size and forecast, by End User
    • 7.3.5.4. Spain
    • 7.3.5.4.1. Market size and forecast, by Product Type
    • 7.3.5.4.2. Market size and forecast, by Applications
    • 7.3.5.4.3. Market size and forecast, by End User
    • 7.3.5.5. Italy
    • 7.3.5.5.1. Market size and forecast, by Product Type
    • 7.3.5.5.2. Market size and forecast, by Applications
    • 7.3.5.5.3. Market size and forecast, by End User
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Market size and forecast, by Product Type
    • 7.3.5.6.2. Market size and forecast, by Applications
    • 7.3.5.6.3. Market size and forecast, by End User
• 7.4. Asia-Pacific
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by Product Type
  • 7.4.3. Market size and forecast, by Applications
  • 7.4.4. Market size and forecast, by End User
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. China
    • 7.4.5.1.1. Market size and forecast, by Product Type
    • 7.4.5.1.2. Market size and forecast, by Applications
    • 7.4.5.1.3. Market size and forecast, by End User
    • 7.4.5.2. Japan
    • 7.4.5.2.1. Market size and forecast, by Product Type
    • 7.4.5.2.2. Market size and forecast, by Applications
    • 7.4.5.2.3. Market size and forecast, by End User
    • 7.4.5.3. India
    • 7.4.5.3.1. Market size and forecast, by Product Type
    • 7.4.5.3.2. Market size and forecast, by Applications
    • 7.4.5.3.3. Market size and forecast, by End User
    • 7.4.5.4. South Korea
    • 7.4.5.4.1. Market size and forecast, by Product Type
    • 7.4.5.4.2. Market size and forecast, by Applications
    • 7.4.5.4.3. Market size and forecast, by End User
    • 7.4.5.5. Australia
    • 7.4.5.5.1. Market size and forecast, by Product Type
    • 7.4.5.5.2. Market size and forecast, by Applications
    • 7.4.5.5.3. Market size and forecast, by End User
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Market size and forecast, by Product Type
    • 7.4.5.6.2. Market size and forecast, by Applications
    • 7.4.5.6.3. Market size and forecast, by End User
• 7.5. LAMEA
  • 7.5.1. Key market trends, growth factors and opportunities
  • 7.5.2. Market size and forecast, by Product Type
  • 7.5.3. Market size and forecast, by Applications
  • 7.5.4. Market size and forecast, by End User
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Market size and forecast, by Product Type
    • 7.5.5.1.2. Market size and forecast, by Applications
    • 7.5.5.1.3. Market size and forecast, by End User
    • 7.5.5.2. UAE
    • 7.5.5.2.1. Market size and forecast, by Product Type
    • 7.5.5.2.2. Market size and forecast, by Applications
    • 7.5.5.2.3. Market size and forecast, by End User
    • 7.5.5.3. Saudi Arabia
    • 7.5.5.3.1. Market size and forecast, by Product Type
    • 7.5.5.3.2. Market size and forecast, by Applications
    • 7.5.5.3.3. Market size and forecast, by End User
    • 7.5.5.4. South Africa
    • 7.5.5.4.1. Market size and forecast, by Product Type
    • 7.5.5.4.2. Market size and forecast, by Applications
    • 7.5.5.4.3. Market size and forecast, by End User
    • 7.5.5.5. Rest of LAMEA
    • 7.5.5.5.1. Market size and forecast, by Product Type
    • 7.5.5.5.2. Market size and forecast, by Applications
    • 7.5.5.5.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product mapping of top 10 player
• 8.4. Competitive dashboard
• 8.5. Competitive heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. Cura Integrative Medicine
  • 9.1.1. Company overview
  • 9.1.2. Key executives
  • 9.1.3. Company snapshot
• 9.2. Holistic Health
  • 9.2.1. Company overview
  • 9.2.2. Key executives
  • 9.2.3. Company snapshot
• 9.3. Metagenics, Inc.
  • 9.3.1. Company overview
  • 9.3.2. Key executives
  • 9.3.3. Company snapshot
• 9.4. GX Sciences Inc.
  • 9.4.1. Company overview
  • 9.4.2. Key executives
  • 9.4.3. Company snapshot
• 9.5. The Gene Box
  • 9.5.1. Company overview
  • 9.5.2. Key executives
  • 9.5.3. Company snapshot
• 9.6. Nutrigenomix Inc.
  • 9.6.1. Company overview
  • 9.6.2. Key executives
  • 9.6.3. Company snapshot
• 9.7. Xcode Life
  • 9.7.1. Company overview
  • 9.7.2. Key executives
  • 9.7.3. Company snapshot
• 9.8. DNA Life
  • 9.8.1. Company overview
  • 9.8.2. Key executives
  • 9.8.3. Company snapshot
• 9.9. Interleukin Genetics
  • 9.9.1. Company overview
  • 9.9.2. Key executives
  • 9.9.3. Company snapshot
• 9.10. Genova Diagnostics
  • 9.10.1. Company overview
  • 9.10.2. Key executives
  • 9.10.3. Company snapshot